David Colcher
Overview
Explore the profile of David Colcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zain J, Tsai N, Palmer J, Simpson J, Adhikarla V, Bading J, et al.
Blood Adv
. 2024 Jun;
8(18):4812-4822.
PMID: 38838232
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission...
2.
Herrera A, Palmer J, Adhikarla V, Yamauchi D, Poku E, Bading J, et al.
Blood Adv
. 2021 Oct;
5(23):5300-5311.
PMID: 34638132
High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with poor outcomes after conventional salvage therapy and autologous hematopoietic cell transplantation (AHCT). Post-AHCT consolidation with brentuximab vedotin (BV)...
3.
Krishnan A, Adhikarla V, Poku E, Palmer J, Chaudhry A, Biglang-Awa V, et al.
Blood Adv
. 2020 Oct;
4(20):5194-5202.
PMID: 33095874
18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which...
4.
TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using Ac-Labeled DOTAylated-huCC49 Antibody
Minnix M, Li L, Yazaki P, Miller A, Chea J, Poku E, et al.
J Nucl Med
. 2020 Jul;
62(1):55-61.
PMID: 32620701
Radioimmunotherapy, an approach using radiolabeled antibodies, has had minimal success in the clinic with several β-emitting radionuclides for the treatment of ovarian cancer. Alternatively, radioimmunotherapy with α-emitters offers the advantage...
5.
Minnix M, Li L, Yazaki P, Chea J, Poku E, Colcher D, et al.
Cancer Med
. 2020 May;
9(13):4756-4767.
PMID: 32368864
Introduction: Ovarian cancer has only a 17% 5-year survival rate in patients diagnosed with late stage disease. Tumor-associated glycoprotein-72 (TAG72), expressed in 88% of all stages of ovarian cancer, is...
6.
Kujawski M, Sherman M, Hui S, Zuro D, Lee W, Yazaki P, et al.
Oncoimmunology
. 2020 Mar;
9(1):1724052.
PMID: 32117587
While anti-CEA antibodies have no direct effect on CEA-positive tumors, they can be used to direct potent anti-tumor effects as an antibody-IL-2 fusion protein (immunocytokine, ICK), and at the same...
7.
Akhavan D, Yazaki P, Yamauchi D, Simpson J, Frankel P, Bading J, et al.
Cancer Biother Radiopharm
. 2020 Jan;
35(1):10-15.
PMID: 31910346
M5A is a humanized monoclonal antibody (mAb) directed against carcinoembryonic antigen (CEA) The purpose of this first in human phase I dose-escalation trial was to characterize the toxicities and determine...
8.
Srideshikan S, Brooks J, Zuro D, Kumar B, Sanchez J, Parra L, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7463-7474.
PMID: 31548348
Purpose: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies...
9.
Murad J, Kozlowska A, Lee H, Ramamurthy M, Chang W, Yazaki P, et al.
Front Immunol
. 2018 Dec;
9:2268.
PMID: 30510550
Impressive clinical efficacy of chimeric antigen receptor (CAR)-engineered T cell therapy for hematological malignancies have prompted significant efforts in achieving similar responses in solid tumors. The lack of truly restricted...
10.
Weist M, Starr R, Aguilar B, Chea J, Miles J, Poku E, et al.
J Nucl Med
. 2018 May;
59(10):1531-1537.
PMID: 29728514
Chimeric antigen receptor (CAR) T cell therapy is a promising clinical approach for reducing tumor progression and prolonging patient survival. However, improvements in both the safety and the potency of...